Matinas announces results from two LNC-formulated oligonucleotides studies

Matinas BioPharma Holdings announces results from a series of in vivo studies demonstrating successful oral delivery of two LNC-formulated small single-strand oligonucleotides that specifically target key inflammatory cytokines TNFalpha and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases. “These studies demonstrate successful oral delivery and biological activity of two different LNC-formulated small oligonucleotides targeting inflammatory cytokines with reductions in tissue cytokine mRNA in both colitis and psoriasis, along with significant reductions in serum TNFalpha levels in colitis. Commensurate improvements in clinical disease markers and scores were also documented in both models,” said James Ferguson, Matinas’ Chief Medical Officer. Earlier this year, Matinas established the in vitro potency of these proprietary oligonucleotides and their LNC formulations in knocking down their respective cytokine targets in cultured cells. Both were advanced to in vivo studies to evaluate meaningful biological activity in relevant disease models.